clinical trial · NCT07186101
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company·phase2·recruiting·n = 252
Ulcerative ColitisLY4268989MirikizumabLY4268989 Placebo
brief summary
The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.
started
Nov 10, 2025
primary completion
May 1, 2027
completion
Mar 1, 2029
last updated
Sep 22, 2026
official title
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol